ISIS 104838

Drug Profile

ISIS 104838

Alternative Names: TNF-alpha antisense inhibitor - Isis; TNF-alpha inhibitor - Isis; Tumour necrosis factor-alpha inhibitor - Isis

Latest Information Update: 03 Mar 2005

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Anti-inflammatories; Antisense oligonucleotides
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Crohn's disease; Inflammation; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 03 Mar 2005 Discontinued - Phase-II for Rheumatoid arthritis in Canada (SC)
  • 03 Mar 2005 Discontinued - Phase-I for Inflammation in USA (IV)
  • 03 Mar 2005 Discontinued - Phase-I for Crohn's disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top